Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 1.00 |
| ▸ | PPP2CA | P67775 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 1/20 | 1.00 |
| ▸ | TFPI2 | P48307 | 1/20 | 1.00 |
| ▸ | NPY4R | P50391 | 1/20 | 1.00 |
| ▸ | PPP2R5A | Q15172 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PPP6C | O00743 | 1/20 | 1.00 |
| ▸ | PPP5C | P53041 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Okadaic Acid SCHEMBL22024950 | 1.00 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL131485 | 1.00 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL21408784 | 1.00 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL2386832 | 1.00 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL23350437 | 1.00 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL24418495 | 1.00 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL545397 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL4446706 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL29369982 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL545387 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401793-A1 | TREATMENT OF CUTANEOUS DISORDERS | VERRICA PHARMACEUTICALS INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-11147790-B2 | Treatment of cutaneous disorders | VERRICA PHARMACEUTICALS INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200155498-A1 | TREATMENT OF CUTANEOUS DISORDERS | Verrica Pharmaceuticals, Inc (US) | 2020-05-21 | — | — | US | disclosed |
| US-20160193177-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | Varrica Pharmaceuticals. Inc. (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155498-A1 | TREATMENT OF CUTANEOUS DISORDERS | CUTA, CMA1, NISCH | PPM1B 4042/4885PPP2CA 871/4885PTPN1 3309/4885 |
| US-20160193177-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | CUTA, NISCH, WARS1 | PPM1B 4535/4885PPP2CA 1784/4885PTPN1 1800/4885 |
| US-20210401793-A1 | TREATMENT OF CUTANEOUS DISORDERS | CUTA, CMA1, NISCH | PPM1B 4042/4885PPP2CA 871/4885PTPN1 3309/4885 |
| US-11147790-B2 | Treatment of cutaneous disorders | CUTA, CMA1, NISCH | PPM1B 4042/4885PPP2CA 871/4885PTPN1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.